blog | Generate Biomedicines

Skip to content

Login

Login

Subscribe to our Newsletter

Go Back to Home

Go Back to Blog

Nasdaq, 2026, Generate Biomedicines

Generate Biomedicines Sets Terms for $400 Million IPO as Asthma-Focused AI Biotech Advances Generative Protein Platform

$Picture of {{ content.blog_author.display_name }}$ Eric Friedman

Feb 23, 2026 4:06:42 PM

Subscribe to our Newsletter

Email

NONE OF THE CONTENT PUBLISHED ON THE WEBSITE OR MOBILE APP CONSTITUTES A RECOMMENDATION, SOLICITATION, ENDORSEMENT, OR OFFER BY IPO PROPHET™ OR ITS AFFILIATES TO BUY OR SELL ANY SECURITIES, FUTURES, OPTIONS, OR OTHER FINANCIAL INSTRUMENTS, OR PROVIDE ANY INVESTMENT ADVICE OR SERVICE.